Purple Biotech (PPBT) Accounts Payables (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Accounts Payables data on file, last reported at $843000.0 in Q1 2026.

• On a quarterly basis, Accounts Payables fell 2.88% year-over-year to $843000.0 in Q1 2026; TTM through Mar 2026 was $843000.0, a 2.88% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, up 42.27% from the prior year.
• Accounts Payables for Q1 2026 stood at $843000.0, down from $2.1 million in the prior quarter.
• Over the last five years, Accounts Payables for PPBT reached as high as $3.5 million in Q4 2023 and fell as low as $605000.0 in Q3 2025.
• Historically, Accounts Payables has averaged $1.9 million across 5 years, with a median of $1.9 million in 2024.
• Across the five-year window, Accounts Payables jumped 93.51% in 2024 and tumbled 78.01% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $2.1 million in 2022, then soared by 65.67% to $3.5 million in 2023, then plunged by 58.81% to $1.5 million in 2024, then surged by 42.27% to $2.1 million in 2025, then slumped by 59.28% to $843000.0 in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $843000.0 in Q1 2026, $2.1 million in Q4 2025, and $605000.0 in Q3 2025.